E-Mail:
REGROWTH@minoxidil.comThe benefits of topical minoxidil for the
treatment of male pattern baldness (MPB) are dose related and this is the first minoxidil
solution in which a concentration of minoxidil greater than 5% is contained in
an alcohol base. To make a stable, high
concentration minoxidil solution required years of experimentation, research and
development. The results have been rewarding.
Xandrox15 is a clear, light amber colored, very stable solution, containing 15%
minoxidil and 5% azelaic acid with a proven
efficacy in the treatment of MPB. Each 125 mL bottle costs $88.00.
To place orders, please visit the main page of our site.
INTRODUCTION
Q. What is Xandrox15?
A. Xandrox15 is an exclusive Regrowth medication for the treatment of alopecia androgenetica, containing 15% minoxidil and 5% azelaic acid by weight. Xandrox15 is available in 125mL bottles. Each mL of Xandrox15 contains 150mg of minoxidil and 50mg of azelaic acid.
Q. Why is Xandrox15 considered to be a breakthrough product?
A. This is the first minoxidil solution in which the base liquid contains a concentration of minoxidil greater than 5%. Minoxidil had been considered to be soluble in alcohol based solutions only to the extent of slightly less than 5%. To make a stable, high concentration minoxidil solution required years of experimentation, research and development. The result has been rewarding. Xandrox15 is a clear, light amber colored, extremely stable solution, containing 15% minoxidil and 5% azelaic acid with a proven efficacy in the treatment of MPB.
Q. Regrowth already offers a Xandrox 12.5% Lotion. What’s the advantage of a Xandrox15 solution?
A. (1) Convenience. A solution is more convenient to apply to the scalp than a lotion. The tip of the dropper can be placed directly onto the scalp with a minimal amount of solution wasted on coating the hair shafts. Whereas a lotion can be conveniently applied to areas of the scalp with little hair or miniaturized hair, the solution is easily applied anywhere on the scalp, including larger areas of thinning hair.
(2) Stability. Whereas the lotion had a tendency to separate at temperatures above 100o F (38o C), the Xandrox15 solution is stable at subfreezing temperatures to temperatures above 200o F (93o C). There are no problems in regards to keeping the Xandrox15 indoors, outdoors or even in your car.
(3) Efficacy. The hair promoting effects of topical minoxidil are dose related. The additional 2.5% minoxidil concentration combined with the greater absorption of the alcohol based Xandrox15 solution is more effective in recruiting miniaturized hair follicles to mature again and produce a terminal hair shaft.
Q. Is the effectiveness of Xandrox15 superior to Xandrox 12.5% Lotion?
A. It certainly can be. It is well established that the effectiveness of topical minoxidil in treating MPB is dose related. In our test group, patients grew more hair using Xandrox15 in areas where they had been using Xandrox 12.5% Lotion. There appears to be a threshold level of stimulation with minoxidil to which follicles can be recruited to grow terminal hair again. This threshold level will vary considerably among patients depending primarily on their genetic predisposition to MPB and the length of time affected hair follicles have been miniaturized.
Q. Are there any special precautions relating to the 125mLbottles of Xandrox15?
A. Because of the volatility of the ethyl alcohol, the bottle should be tightly capped when the solution is not being used. The solution is extremely stable within a wide range of temperatures and has been tested to be unaffected in the range of 10o to 200o Fahrenheit (-12o to 93o Centigrade) for short exposures. Xandrox15 is best kept at room temperatures.
PHARMACOLOGY
Q. Will Xandrox15 be better absorbed into the dermis of the scalp?
A. Yes. Ethyl alcohol is one of the few substances that freely permeates the skin (the permeability coefficient of ethanol across human skin in 8 x 10 –8 mol/cm2) and it carries the minoxidil in with it. The penetration enhancing effects of ethanol play a significant role in minoxidil absorption. The effective absorption of topical minoxidil depends on the vehicle composition. Greater effects are achieved when the fraction of the volatile component increases, especially at ethanol concentrations higher than 50% (and maximizing at 90%).
Q. Why not apply 3mL of the 5% Xandrox instead of using Xandrox15?
A. The amount of minoxidil in 3mL of 5% Xandrox is the same as the amount of minoxidil in 1mL of Xandrox15. However, in terms of absorption and efficacy, you are much better served by the use of Xandrox15 because (1) the 80% alcohol base of the Xandrox15 allows for significantly greater delivery of minoxidil to the follicles where it is needed; (2) With better patient compliance, your chances of reversing hair loss is improved and there is certainly better patient compliance in applying 1 mL of Xandrox15 than there would be in applying 1 mL of 5% Xandrox 3x/day; (3) the cost of 3 mL of 5% Xandrox is more than 1 mL of Xandrox15; and most importantly (4), there is a threshold level at which atrophied hair follicles will respond to minoxidil to produce a terminal hair shaft again. A 15% minoxidil solution is much more likely to recruit hair follicles to grow again than is a 5% minoxidil solution to do so.
In regards to the second active ingredient, most of the total amount of azelaic acid (150mg) in 3mL of 5% Xandrox would be wasted. 50mg of azelaic acid, which is the amount of azelaic acid in 1mL of Xandrox15, is more than sufficient to effectively inhibit DHT synthesis in the scalp.
Q. Does Xandrox15 leave any kind of residual on the scalp when it dries?
A. When the alcohol has absorbed into the scalp, there will be a slight stickiness due to the residual glycerin, minoxidil and azelaic acid. This residual reservoir of minoxidil provides a beneficial source for the continued absorption of minoxidil even after the Xandrox15 has dried on the scalp. If Xandrox15 is only used at night and applied in small amounts, you can minimize the objections to the residual on the scalp, while you are simultaneously maximizing the absorption of minoxidil.
FORMULATION
Q. How much of the base of Xandrox15 is ethyl alcohol?
A. The base solution consists of 80% ethyl alcohol and 20% glycerin.
Q. Does Xandrox15 have a ‘greasy’ feel?
A. Since the base is 80% ethyl alcohol, Xandrox15 solution absorbs quickly and does not leave an oily sheen on the scalp. Many patients like the extra body the glycerin gives to their hair.
Q. Why use glycerin instead of the propylene glycol that is used in most minoxidil preparations?
A. A significant number of patients, perhaps as many as 10%, have an adverse skin reaction to propylene glycol. On the other hand, it would be extremely rare to have an adverse reaction to glycerin, which is commonly used in dermatological preparations as a humectant. Humectants attract moisture to one’s skin. Glycerin based soaps are offered at exclusive spas and resorts for this very reason.
Q. Why doesn’t Regrowth add vitamin B6 and zinc to Xandrox15?
A. Whereas in vitro experiments demonstrate that the addition of vitamin B6 and zinc to azelaic acid allows azelaic acid to be used in smaller quantities to inhibit the synthesis of DHT in the skin, there are absolutely no studies in regards to the absorption dynamics of topical vitamin B6. Exhaustive research and consultations with the pharmacology departments of many universities yielded no information concerning the absorption, efficacy or safety of topical vitamin B6. Without this vital information, it would be irresponsible and irrational to add vitamin B6 to minoxidil/azelaic acid solutions for the treatment of MPB.
There are studies in regards to the use of topical zinc. However, zinc will form insoluble salts when it reacts with minoxidil/azelaic acid, rendering all of the ingredients ineffective.
For these reasons, it was decided to use azelaic acid as a component of all Xandrox formulations in amounts that will be effective in inhibiting the synthesis of DHT in the scalp for more than three standard deviations (>99%) of the patients
Q. Why wasn’t retinoic acid added to Xandrox15?
A. Retinoic acid was an important additional ingredient when minoxidil solutions only contained 2% minoxidil (Rogaine). With higher concentration minoxidil solutions, there is no need for retinoic acid, which can have more drawbacks than benefits. Retinoic acid acts as a chemical peel and can cause drying, scaling, redness and irritation of the scalp. Moreover, chronic use of retinoic acid makes the skin more sensitive to sun damage.
Q. Why use azelaic acid instead of other agents to decrease the DHT in the scalp?
A. The first choice of topical treatment for MPB would have been to combine spironolactone and minoxidil in solution. Unfortunately, they aren’t compatible in the same solution. Other substances such as emu oil, grape seed extract, linoleic acid, green tea, saw palmetto, etc. may decrease DHT in the scalp, but there are no credible studies to prove their value. The pharmacological actions of azelaic acid are well documented and proven with time.
Q. On a forum someone mentioned that azelaic acid had ‘anti-proliferative and cytotoxic properties’. Is that true?
A. Anti-proliferative means "it prevents the proliferation of cells." and cytotoxic means "it kills cells." So, the answer to the question is, "Yes! But in a beneficial way." Azelaic acid has ‘an anti-proliferative and cytotoxic action' only on malignant cancer cells and pathogenic bacteria. If you read the cited articles (Exp Dermatol. 1995 Apr;4(2):79-81. Effect of azelaic acid on melanoma cells in culture. Lemic-Stojcevic L, Nias AH, Breathnach AS. ; Anticancer Res. 1990 Nov-Dec;10(6):1599-602. Cytotoxic activity of azelaic acid against human melanoma primary cultures and established cell lines. Zaffaroni N, Villa R, Silvestro L, Sanfilippo O, Silvestrini R.; Biochem Pharmacol. 1985 May 15;34(10):1653-8. Activity of azelaic acid on cultures of lymphoma- and leukemia-derived cell lines, normal resting and stimulated lymphocytes and 3T3 fibroblasts. Picardo M, Passi S, Sirianni MC, Fiorilli M, Russo GD, Cortesi E, Barile G, Breathnach AS, Nazzaro-Porro M) carefully, you will realize that azelaic acid has a demonstrated ‘anti-proliferative and cytotoxic action’ only on malignant cells and bacteria. In fact, it is this biochemical action that makes it a useful and beneficial medication. There is no evidence to even suggest that azelaic acid is harmful to hair follicle cells. In fact, the opposite is true. Azelaic acid is used to normalize of keratinization and one of the side effects from the use of azelaic acid can be hypertrichosis.
For a complete and accurate pharmacological description of azelaic acid, please read the information here.
IF CRYSTALLIZATION OCCURS
NOTE: If
crystallization occurs within a bottle of Xandrox15, rest assure,
there would be no detectable change in the efficacy of the formula. On the
average only 1.4% of any minoxidil formula penetrates to the follicles. In this
case, 2.1 mg from 1 mL of 15% formula would penetrate. When a precipitate forms
in the bottles of Xandrox15, only a small amount (less than 1-2%) of the
minoxidil crystallizes. So we are talking about a 0.02 to 0.04 mg change in
delivery to the follicles. It is not possible to be that precise with a spray or
medicine dropper. Excuse the pun, but we are "splitting hairs" in regards to
dosage. If you had been using the Xandrox15 with the precipitate, the changes in
concentration of minoxidil would be negligible.
However, since being made aware of the crystallization problem, all Xandrox15
solutions have been formulated with a 16% concentration of minoxidil. This
increase in concentration won't make any difference in the effectiveness of the
solution, but Dr. Lee felt the necessity for the change as a matter of honesty
in advertising and labeling.
DIRECTIONS FOR USE
Q. How is Xandrox15 applied to the scalp?
Q. Is there an alternative method of application other than using a dropper or sprayer?
A. Regrowth offers a 2oz. plastic bottle with a custom fitted dauber applicator with protective overcap. Xandrox15 can be transferred to the applicator bottle and dispensed by simply inverting the dauber and gliding it across the scalp. It has been established that four side-to-side passes over the scalp approximate 1 mL of dispensed solution. This is, by far, the most convenient way to apply topical minoxidil solutions. Although the amount being dispensed cannot be precisely calibrated, if only enough liquid is applied to moisten the affected areas, there is minimal chance of utilizing excessive amounts of Xandrox15.
Q. Should the scalp be dry or wet when Xandrox15 is applied?
A. The scalp can be dry or hydrated, but the scalp should not be wet to the degree of diluting or washing off the minoxidil/azelaic acid.
Q. How soon after applying Xandrox15 can one shower or shampoo?
A. For optimal absorption of the minoxidil and azelaic acid, allow one hour. The high concentration of ethyl alcohol in the base allows for rapid absorption of the minoxidil.
Q. Will wetting the hair for styling purposes affect the efficacy of Xandrox 15%
A. No, assuming you are not going to get the scalp so wet that you will wash off the Xandrox 15.
Q. Will blow-drying the hair affect the efficacy of Xandrox15?
A. It would be advisable to blow-dry the hair before the application of Xandrox15. Otherwise, blow-drying will cause most of the Xandrox15 to evaporate rather than to absorb. Applying 1mL of Xandrox15 to the scalp should not significantly alter the appearance of the hair style.
Q. What do I do if a precipitate forms in my bottle of Xandrox15?
A. Since the Xandrox15 is a highly saturated solution of minoxidil, there may be rare occasions when a precipitate will form in the bottle. If and when this happens, the capped bottle of Xandrox15 should be placed in water that has been heated to gently simmering temperatures and shaken vigorously. As long as the bottle of Xandrox15 is kept tightly capped, it can be kept in the heated water for prolonged periods, until all the minoxidil goes back into solution.
USE WITH OTHER PRODUCTS
Q. Wouldn’t it be more beneficial to use Xandrox15 twice daily, rather than to alternate its use with a lower concentration minoxidil solution?
A. Possibly, but it’s neither necessary nor advisable to do so. The potency of Xandrox15 in combination with a 5% Xandrox or a 5% Minoxidil solution is usually sufficient to obtain optimal results in treating MPB.
Q. Can Xandrox15 be used in conjunction with 5% Xandrox?
A. Yes. Apply 1mL of either solution once/day. The applications should be at least 8 hours apart. If nighttime a Xandrox solution containing 0.025% retinoic acid is used, it should be applied at night and Xandrox15 should be applied in the morning.
Q. Can Xandrox15 be used in conjunction with the 5% Minoxidil Solution?
A. Yes. Apply 1mL of either solution once/day. The applications should be at least 8 hours apart. To further decrease the amount and the action of DHT in the scalp, apply 5% Spironolactone Lotion after applying the 5% Minoxidil Solution.
Q. Should one use the 5% Spironolactone Lotion in conjunction with Xandrox15?
A. For most patients, it shouldn’t be necessary. The azelaic acid in Xandrox15 inhibits the synthesis of DHT in almost all cases. However, if one opts to use a 5% minoxidil solution without azelaic acid for the second application of the day, then the additional use of the 5% Spironolactone Lotion is advisable. Most patients use the 5% Spironolactone Lotion at night. Apply the Xandrox15 solution first. Allow 10-15 minutes for it to partially dry. And then apply a thin film of 5% Spironolactone Lotion directly on top of the Xandrox15.
Q. Should a patient initiate treatment for MPB with Xandrox15?
A. No. As a rule, most patients will have a satisfactory response to Xandrox 5% solutions or to the combination of a 5% Minoxidil solution with the use of the 5% Spironolactone Lotion. If, after at least six months of treatment with either of these regimes, the improvement is not satisfactory, then the patient may want to consider the use of Xandrox15 on those areas of the scalp with inadequate regrowth of hair.
The second reason why a patient should not begin treatment of MPB with Xandrox15 is because topical minoxidil can allow hair that is already in the telogen phase to shed before the end of the phase. Although the hair is replaced, hopefully with thicker hair, the observation of increased shedding, however temporary, may have a psychologically damaging effect.
SIDE EFFECTS AND CONTRAINDICATIONS
Q. What is the margin of safety from having systemic effects due to minoxidil when dosing with Xandrox15 daily?
Minoxidil requires a serum concentration of 20 ng/mL to have any hemodynamic or other systemic effect in the human body. Allowing for the average 1.4% absorption (range 0.3 - 4.5%) of minoxidil from the topical application of 1 mL of Xandrox15,
there will be a serum concentration of minoxidil of ~4 ng / mL of minoxidil in the serum. So, there is an estimated 5-fold safety margin from any systemic effects of minoxidil due to the use of Xandrox15, when it is used once/day. For optimal results, it is suggested that topical minoxidil be applied twice/day. One dose should be 1mL Xandrox15 and the second dose, at least 8 hours apart, should be 1mL of the lower concentration Xandrox 5% or 5% Minoxidil. If the second daily application is 5% Minoxidil, using it with topical spironolactone will inhibit the DHT and stimulate hair growth where they are applied.
Our incidence of having any systemic side effects with the Xandrox 12.5% Lotion is less than 1 patient per 1500.
Q. What are the systemic effects and possible side effects of minoxidil use?
A. Oral minoxidil is used as a medication to lower the blood pressure, so the most common systemic effects are tachycardia (increased heart rate) and orthostatic hypotension (dizzyness on standing). Other side effects may include fluid retention,
chest pain and facial edema. There have been rare reports of pericardial effusion (fluid collection around the heart) with the use of oral minoxidil.
Q. Wouldn’t the amount of alcohol used in Xandrox15 be harmful?
A. Not at all. At most, 1mL of Xandrox15 and 1mL of another minoxidil solution would be applied daily. Given the volatility of ethyl alcohol, the maximum exposure period after each topical application would be significantly less than 1 hour. The application area would be less than 200 cm2. The percutaneous absorption from an 80% ethyl alcohol solution would be less than 50mg. By comparison, this is the amount of alcohol in less than 1 mL of wine (10% alcohol by volume). Skin exposure is not a safety concern.
Q. What should a patient do, if he or she experiences any of the systemic side effects of minoxidil?
A. The patient should immediately cease using all topical solutions, which contain minoxidil. Side effects should abate within days. Report your side effects immediately to Regrowth (RichardLeeMD@earthlink.net). Following cessation of the topical application of minoxidil, approximately 95% of systemically absorbed minoxidil is eliminated within four days.
Q. Are there patients who should avoid using Xandrox15?
A. Yes. Patients with any history of heart disease should not use Xandrox15. Also patients who have a known adverse reaction to minoxidil should avoid using Xandrox15.
PACKAGE INSERT
XANDROX15
THE SOLUTION
XANDROX15 is a custom formulated solution containing 15% minoxidil and 5% azelaic acid. Xandrox15 is prescribed and dispensed exclusively for the patients of Regrowth to treat areas of alopecia androgenetica that are or have been resistant to other forms of therapy
Minoxidil 15%
Description: Minoxidil topical solution is a non-specific hair growth stimulant. Minoxidil appears as a white or off-white, odorless crystalline solid that is soluble in water to the extent of approximately 2 mg/mL, but more readily soluble in glycerin or ethanol. The chemical name for minoxidil is 2, 4-pyrimidinediamine, 6-(1-piperinedinyl)-, 3-oxide (MW= 209.25). Xandrox15 contains 150 mg minoxidil per milliliter.
Clinical Pharmacology: Minoxidil topical solutions stimulate hair growth in individuals with androgenetic alopecia, typically expressed in males as thinning of the hair at the vertex, crown, temporal and/or frontal areas and in females usually as diffuse hair loss or thinning in the frontoparietal areas. The exact mechanism by which minoxidil stimulates hair growth is not known but is thought to have a direct effect on the hair follicle to sustain the anagen phase of the hair cycle. It has also been shown to have a vasodilatory effect on the scalp. Although minoxidil is a direct acting peripheral arterial dilator that reduces blood pressure by decreasing peripheral vascular resistance, the vasodilating effect of minoxidil has not been proven to directly result in hair growth. The failure to detect evidence of systemic effects during treatment with topical minoxidil reflects the poor absorption of topical minoxidil, which averages about 1.4% (range 0.3 to 4.5%) from normal intact scalp. Since it requires 20 ng / mL of serum to have any systemic effects in the human body and allowing for an average absorption rate of 1.4%, there remains a greater than 5-fold safety margin in the use of Xandrox15. Following cessation of topical dosing of minoxidil, approximately 95% of systemically absorbed minoxidil is eliminated within four days. Minoxidil and its metabolites are excreted principally in the urine.
Indications and Usage: Xandrox15 topical solution is indicated for the treatment of alopecia androgenetica in men and women. At least four months of once daily applications are usually required before evidence of hair growth can be expected. Even in patients for whom topical minoxidil does not seem effective for restoring hair loss, for most patients it will prevent further thinning and loss due to alopecia androgenetica.
Contraindications: Xandrox15 is contraindicated for any patient with a hypersensitivity to any of the components of the preparation. Xandrox15 should also not be used by any patient with a known cardiac abnormality.
Warnings: Although extensive use of topical minoxidil has not revealed evidence that enough minoxidil is absorbed to have systemic effects, greater absorption or individual variability or sensitivity could theoretically cause a systemic effect. If systemic effects were to occur, patients with underlying heart disease would be at particular risk. Minoxidil could also have additive effects with other therapies in patients being treated for hypertension.
Drug Interactions: There are no known drug interactions associated with the use of a topical minoxidil solution.
Adverse Reactions: In placebo controlled trials, the rate of adverse reactions were no more common, other than dermatologic events such as irritation and allergic dermatitis.
Overdosage: There have been no reported cases of overdosage resulting from topical minoxidil administration. Minoxidil and its metabolites are hemodialyzable.
Azelaic Acid 5%
Description: Azelaic acid is a naturally occurring saturated dicarboxylic acid with the chemical name of 1,7-heptanedicarboxylic acid and a molecular weight of 188.22. Azelaic acid is a dietary component of whole grain cereals and animal products.
Clinical Pharmacology: The exact mechanism of action of azelaic acid is not known. Azelaic acid at high concentrations is bactericidal. In vitro, azelaic acid acted as a scavenger of oxy radicals and inhibits a variety of oxidoreductive enzymes including 5-alpha reductase. Azelaic acid (0.1 to 3.0 mmol/l) has been shown to produce a competitive concentration dependent inhibition of 5-alpha reductase activity in homogenates of human foreskin. The multiple actions of azelaic acid cause a normalization of keratinization and a decrease in the free fatty acid content of skin surface lipids.
Pharmacodynamics: Following a single application to human skin, 3% to 5% of the azelaic acid penetrates into the strateum corneum (up to 10% is present in the dermis and epidermis). There is negligible cutaneous metabolism after topical application. Approximately 4% of topically applied azelaic acid is systemically absorbed and mainly excreted unchanged in the urine. The half-life is approximately 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics. After topical treatment with azelaic acid, plasma concentration and urinary excretion are not significantly different from baseline levels.
Contraindications: XANDROX15 is contraindicated in individuals who have known hypersensitivity to any of its components.
Warnings: There have been isolated reports of hypopigmentation after use of azelaic acid, although there is no depigmenting effect on normal melanocytes.
Precautions: If sensitivity or severe irritation develops with the use of XANDROX15, treatment should be discontinued. The most common adverse reactions occurring in approximately 1%-5% of patients were pruritis, burning, stinging and tingling, usually at the start of treatment. These reactions may last 5 to 20 minutes, especially if the skin is inflamed or broken. The adverse effects commonly subside if treatment is continued. Other adverse reactions such as erythema, dryness, rash, peeling, irritation and dermatitis were reported in less than 1% of patients. The following additional adverse experiences have been rarely reported: worsening of asthma, vitilago hypopigmentation, hypertrichosis and reddening (signs of keratosis pilaris). Note: azelaic acid will consistently lighten hyperpigmented skin (skin that is darker than normal for a given individual) but will not typically lighten skin beyond its normal color. Rarely, patients with dark complexions may notice hypopigmentation of skin. There are no systemic adverse effects.
Considerations: Azelaic acid is normally found in the human diet and is not considered to be a carcinogenic substance. Mutagenicity studies are negative and animal studies have shown no adverse effects on fertility or reproduction. Human problems have not been reported during pregnancy.
Dosage and Administration: Hair and scalp can be dry or hydrated prior to topical application of XANDROX15. A total daily dose of 1 mL should be applied to the affected areas of the scalp where regrowth of hair has been resistant to treatment. Each bottle of Xandrox15 is accompanied with a medicine dropper calibrated at 1mL If you choose to use the dropper, place the tip of the dropper onto the scalp and squeeze the rubber bulb to release a small amount of Xandrox15. Divide the total 1mL quantity into as many smaller aliquots as are required to moisten/wet the scalp in all the areas affected by MPB. The fingertips can be used to spread the liquid within the desired areas and/or to restrict the flow to other areas. Wash hands thereafter.
Regrowth offers a 2 oz. Plastic bottle with a custom fitted dauber applicator with a protective overcap. Xandrox15 can be transferred to the applicator bottle and dispensed by inverting the dauber and gliding it across the scalp, while gently squeezing the plastic bottle. Four side-to-side passes over the scalp approximates dispensing 1ml of Xandrox15 solution. Although the amount of solution being dispensed cannot be precisely calibrated using the dauber applicator, if only enough liquid is applied to moisten the affected areas, there is minimal chance of utilizing excessive amounts of Xandrox15.
Daily applications for four months or longer may be required before evidence of hair growth is observed. Onset and degree of hair growth is variable among patients. XANDROX15 is best used in conjunction with lower concentration Xandrox solutions and/or lower concentration minoxidil solutions along with an agent to decrease the DHT in the scalp. Topical minoxidil should be applied to the scalp twice/day at least 8 hours apart.
How Supplied: XANDROX15 is available in 125mL bottles and is dispensed exclusively by Regrowth.
Storage: XANDROX15 solution is best kept at normal room temperatures. XANDROX15 can be kept for up to 24 months without deterioration or loss of efficacy.
Sources: Complete bibliography and references are posted here.
Regrowth
7049 Greenleaf Avenue
Whittier, CA 90602
www.minoxidil.com
Home |
5% Minoxidil Solutions
| Minoxidil + Retin-A
| Finasteride (Proscar)
History & Philosophy |
FAQ's
How to Obtain High
Concentration MINOXIDIL Solutions and FINASTERIDE
E-Mail:
REGROWTH@minoxidil.com
©1997 Regrowth.